Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.
The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil. Despite a warning by the manufacturer, only one report of this interaction has been published in the literature. This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.
Rindone
J P
JP
Veterans Affairs Medical Center, Prescott, Ariz 86313, USA.
Keng
H C
HC
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D004347:Drug Interactions; D005500:Follow-Up Studies; D015248:Gemfibrozil / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D007020:Hypoprothrombinemias / Q000139:chemically induced*; D008297:Male; D013924:Thrombophlebitis / Q000188:drug therapy; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D000960:Hypolipidemic Agents; D014859:Warfarin; D015248:Gemfibrozil